NOVACYT |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.817 EUR | +0.86% |
|
+14.43% | +14.59% |
| Apr. 19 | Novacyt: confident ahead of DHSC trial | CF |
| Apr. 19 | Novacyt expects court to dismiss application by UK DHSC | AN |
| Sales 2021 | 95.78M 102M | Sales 2022 | 21.04M 22.49M | Capitalization | 76.79M 82.08M |
|---|---|---|---|---|---|
| Net income 2021 | -9M -9.62M | Net income 2022 | -25M -26.72M | EV / Sales 2021 | 1.67 x |
| Net cash position 2021 | 99.9M 107M | Net cash position 2022 | 86.29M 92.24M | EV / Sales 2022 | -0.45 x |
| P/E ratio 2021 |
-26.3
x | P/E ratio 2022 |
-2.99
x | Employees | 120 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 96.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novacyt
More news
| 1 week | +13.45% | ||
| Current month | +56.67% | ||
| 1 month | +55.32% | ||
| 3 months | +45.16% | ||
| 6 months | +50.00% | ||
| Current year | +13.60% |
1 week
0.74
0.87
1 month
0.510.87
Current year
0.490.87
1 year
0.421.00
3 years
0.426.72
5 years
0.0613.96
10 years
0.0613.96
| Managers | Title | Age | Since |
|---|---|---|---|
James McCarthy
CEO | Chief Executive Officer | 58 | 21-01-04 |
Steven Gibson
DFI | Director of Finance/CFO | 41 | 17-03-31 |
Paul Oladimeji
CTO | Chief Tech/Sci/R&D Officer | - | 16-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Heath
BRD | Director/Board Member | 76 | 15-06-28 |
John Brown
BRD | Director/Board Member | 69 | 23-09-07 |
Lyn Rees
BRD | Director/Board Member | 51 | 23-09-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.817 | +0.86% | 155 442 |
| 24-04-23 | 0.81 | +3.85% | 341,386 |
| 24-04-22 | 0.78 | -6.02% | 634,794 |
| 24-04-19 | 0.83 | +10.67% | 1,517,074 |
| 24-04-18 | 0.75 | +5.04% | 1,093,529 |
Real-time Euronext Paris, April 24, 2024 at 04:29 am EDT
More quotes
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors:
- development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
- manufacture and sale of molecular screening kits (Primerdesign): for laboratories.
Calendar
2024-04-24
- Q4 2023 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +13.60% | 61.14M | |
| -25.77% | 961M | |
| -19.12% | 131M | |
| +10.84% | 63.05M | |
| -15.49% | 61.84M | |
| -1.20% | 50.36M |
- Stock Market
- Equities
- ALNOV Stock
